Cell Signaling Technology Logo - Extra Large
1% for the planet logo

Podoplanin (LpMab-12) & CO-0199-750 SignalStar® Oligo-Antibody Pair #92798

Filter:
  • IHC

Order Information # 92798

This product is not sold separately. Please see the SignalStar® Multiplex IHC Panel Builder Tool for ordering information.

    Product Information

    Product Usage Information

    Application Dilution
    SignalStar™ Leica Bond 1:50 - 1:200
    SignalStar™ Manual 1:50 - 1:200

    Storage

    SignalStar conjugates are supplied in PBS (pH 7.2), less than 0.1% sodium azide, 2 mM EDTA, 0.05% Triton X-100, 2 mg/mL BSA, and 50% glycerol. Complementary oligos are supplied in nuclease-free water. Store at -20°C. Do not aliquot the antibody. All components in this kit are stable for at least 12 months when stored at the recommended temperature.

    Product Description

    SignalStar multiplex immunohistochemistry (IHC) is an advanced technology for labeling multiple proteins simultaneously in tissue samples using specific primary antibodies and fluorescent detection reagents. This technology offers accuracy and reliability in visualizing and analyzing protein expression while maintaining spatial context and tissue architecture.

    SignalStar Oligo-Antibody Pairs are compatible with the SignalStar Multiplex IHC Buffer Kits for use in fluorescent multiplex imaging experiments. This product includes the oligo-conjugated antibodies and complementary oligos required for labeling your target protein on up to 10 slides. SignalStar Multiplex IHC Buffer Kits are required to amplify and image the target signal. Multiple oligo-antibody pairs can be conveniently combined into a multiplex panel using the SignalStar Multiplex IHC Panel Builder. SignalStar Multiplex IHC Kits & Reagents are not compatible with all of Cell Signaling Technology® products and protocols that are recommended for use in immunohistochemical assays.

    Protocol

    Specificity / Sensitivity

    Podoplanin (LpMab-12) Mouse mAb (SignalStar® Conjugate 0199) recognizes podoplanin that is sialylated on Thr52 in the third platelet aggregation domain (PLAG3) of human podoplanin (10).

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with LN-229 glioma cells expressing human podoplanin.

    Background

    Podoplanin (aggrus, glycoprotein 36) is a single-pass transmembrane protein belonging to the type-1 family of sialomucin-like glycoproteins. Podoplanin was first described in the rat as a surface glycoprotein that regulated podocyte morphology (1). It is now commonly used as a marker of lymphatic endothelial cells, where its expression is associated with the process of lymphangiogenesis (2). Its role in this regard is presumably due to its putative involvement in regulating actin cytoskeleton dynamics (3). Research studies have shown that podoplanin expression is upregulated in a number of tumor types including colorectal cancers (4), oral squamous cell carcinomas (5), and germ cell tumors (6), with higher expression levels often associated with more aggressive tumors (7). Research studies have suggested a functional role for podoplanin in the stromal microenvironment of tumors. For example, it has been reported that podoplanin expression in cancer-associated fibroblasts (CAFs) is positively associated with a stromal environment that promotes cancer progression (8,9).
    Podoplanin is O-glycosylated at multiple sites in the extracellular domain, including disialylation at Thr52 in the third platelet-aggregation (PLAG3) domain (10). Research studies have shown that glycoylation at this site is required for tumor cell-induced platelet aggregation activity (11).
    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStar is a registered trademark of Cell Signaling Technology, Inc.
    U.S. Patent No. 10,781,477, foreign equivalents, and child patents deriving therefrom.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.